Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758228 | 1.00 | RIPK1 (0.51) | RIPK1LMNAALDH1A1L3MBTL1TAS1R3 | |
| SCHEMBL5758365 | 0.95 | ALDH1A1 (0.55) | LMNAALDH1A1L3MBTL1TAS1R3TAS1R1 | |
| SCHEMBL5757044 | 0.83 | ELANE (0.53) | LMNAALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5757779 | 0.78 | TAS1R3 (0.53) | LMNAALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5757916 | 0.78 | NOTUM (0.47) | RIPK1PDE4BPDE4DNOTUM | |
| SCHEMBL5755397 | 0.76 | NOTUM (0.44) | RIPK1PDE10ANOTUM | |
| SCHEMBL5757705 | 0.75 | ELANE (0.55) | ALDH1A1NOTUM | |
| SCHEMBL5756499 | 0.74 | CNR1 (0.54) | LMNAALDH1A1L3MBTL1NOTUM | |
| SCHEMBL5758147 | 0.73 | HPGD (0.47) | LMNAALDH1A1PDE10ANOTUM | |
| SCHEMBL5756352 | 0.72 | DRD2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | RIPK1 3651/4885LMNA 509/4885ALDH1A1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.